Bernstein Initiates Coverage On Jazz Pharmaceuticals with Market Perform Rating, Announces Price Target of $229

Benzinga Newsdesk www.benzinga.com Neutral 59.7%

Neg 0% Neu 59.7% Pos 0%

Bernstein analyst Jeffrey Walch initiates coverage on Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Market Perform rating and announces Price Target of $229.